MEDIUM confidence: 100% data completeness, but the composite (45) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $155 (last qtr, 6 analysts) → $150 (last mo, 3) (-2.7%).
Buy-rated share 76% → 83% over ~3 months (+7pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.26 | $0.45 | +72.9% |
| May 2026 | $0.27 | $0.44 | +65.5% |
| Feb 2026 | $0.38 | $0.44 | +15.8% |
| Nov 2025 | $0.31 | $0.33 | +6.5% |
| Aug 2025 | $0.47 | $0.59 | +25.5% |
| May 2025 | $0.45 | $0.56 | +24.4% |
| Feb 2025 | $0.35 | $0.49 | +40.0% |
| Nov 2024 | $0.40 | $0.52 | +30.0% |
Net insider -$571.4M over 180 days (0 open-market buys, 31 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $429M— | $576M+34.5% | $693M+20.2% | $781M+12.7% | $901M+15.5% |
| EPS (dil.) | $-0.18— | $-0.24n/m | $0.20n/m | $0.89+345.0% | $2.52+183.1% |
| Free Cash Flow | $24M— | $75M+212.0% | $110M+47.0% | $96M-12.6% | $41M-57.3% |
| Gross Margin | 60.2% | 63.2%+3.0pp | 59.0%-4.2pp | 59.7%+0.7pp | 59.9%+0.2pp |
| Operating Margin | -2.6% | -4.5%-1.8pp | 1.7%+6.2pp | 11.7%+9.9pp | 17.4%+5.8pp |
| Net Margin | -4.6% | -4.8%-0.3pp | 2.8%+7.6pp | 10.8%+8.0pp | 28.8%+17.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 34.5%/yr (revenue basis).
Base free cash flow $82M (avg FY2023–FY2025; latest year $41M) · equity value $10.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 45 for DOCN suggests a neutral outlook, driven by a mix of factors. The stock scores high on profitability, with a notable ROE of 54.7%, and exhibits strong momentum, having returned 126.4% over the past year. However, it trades at a premium, with a P/E of 34.7, and scores lower on risk due to high volatility and a beta of 1.7, which may indicate a higher level of uncertainty. The long-term and short-term scores are relatively aligned, indicating a consistent view across different time horizons.